血清免疫球蛋白A、免疫球蛋白G、补体C3、补体C4与多发性骨髓瘤患者经含硼替佐米方案治疗疗效的关系  

Relationship between serum immunoglobulin A,immunoglobulin G,complement C3,complement C4 and the therapeutic efficacy of bortezomib containing regimen in patients with multiple myeloma

作　　者：卢秀利 武金日 赵玉洁 LU Xiuli;WU Jinri;ZHAO Yujie(Department of Hematology,the Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,He’nan,China)

机构地区：[1]新乡医学院第三附属医院血液内科,河南新乡453000

出　　处：《癌症进展》2025年第1期95-98,114,共5页Oncology Progress

摘　　要：目的探讨血清免疫球蛋白(Ig)A、IgG、补体C3、补体C4与多发性骨髓瘤(MM)患者经含硼替佐米方案治疗疗效的关系。方法选取80例MM患者,经含硼替佐米方案治疗后,依据疗效评估结果分为有效组、无效组。MM患者经含硼替佐米方案治疗疗效的影响因素采用多因素Logistic回归分析;绘制受试者工作特征(ROC)曲线,计算曲线下面积(AUC),评估IgA、IgG、补体C3、补体C4单独及联合检测对MM患者含硼替佐米方案治疗疗效的预测价值。结果80例MM患者经含硼替佐米方案治疗3个周期后,完全缓解10例,非常好的部分缓解32例,部分缓解19例,疾病稳定10例,疾病进展9例,治疗有效61例,治疗无效19例,分别作为有效组和无效组。无效组经含硼替佐米方案治疗MM患者血清IgA、IgG、补体C3、补体C4水平均明显高于有效组,差异均有统计学意义(P﹤0.01)。多因素Logistic回归分析结果显示,血清IgA、IgG、补体C3、补体C4水平升高均是MM患者经含硼替佐米方案治疗疗效的独立危险因素(P﹤0.05)。ROC曲线显示,IgA、IgG、补体C3、补体C4联合检测预测MM患者经含硼替佐米方案治疗疗效的AUC为0.902(95%CI:0.852~0.949),高于各指标单独检测。结论血清IgA、IgG、补体C3、补体C4水平升高均是MM患者经含硼替佐米方案治疗疗效的独立危险因素,四者联合检测对MM患者经含硼替佐米方案治疗疗效的预测价值较高。Objective To analyze the relationship between serum immunoglobulin(Ig)A,IgG,complement C3,complement C4 and the therapeutic efficacy of bortezomib containing regimen in patients with multiple myeloma(MM).Method A total of 80 MM patients were selected and treated with bortezomib containing regimen.Based on the efficacy evaluation results,they were divided into effective group and ineffective group.Multivariate Logistic regression analysis was used to investigate the influencing factors of the therapeutic efficacy of bortezomib containing regimen in MM patients.The receiver operating characteristic(ROC)curve was drawn,the area under the curve(AUC)was calculated,and the predictive value of IgA,IgG,complement C3 and complement C4 single and combined detection for therapeutic efficacy of bortezomib containing regimen in MM patients were evaluated.Result A total of 80 MM patients were treated with bortezomib containing regimen for 3 cycles,it was found that 10 cases had complete response,32 cases had very good partial response,19 cases had partial response,10 cases had stable disease,9 cases had disease progression,61 cases were effective in treatment,and 19 cases were ineffective in treatment,they were divided into effective group and ineffective group.The serum levels of IgA,IgG,complement C3 and complement C4 in ineffective group were significantly higher than those in effective group,and the differences were statistically significant(P<0.01).Multivariate Logistic regression analysis showed that serum levels of IgA,IgG,complement C3 and complement C4 were independent risk factors for the therapeutic efficacy of bortezomib containing regimen in MM patients(P<0.05).ROC curve showed that the AUC of IgA,IgG,complement C3 and complement C4 combined detection in predicting the therapeutic efficacy of bortezomib containing regimen in MM patients was 0.902(95%CI:0.852-0.949),which was higher than the individual detection of each indicator.Conclusion Serum levels of IgA,IgG,complement C3 and complement C4 are independent ris

关 键 词：免疫球蛋白 补体 硼替佐米 多发性骨髓瘤 临床疗效 

分 类 号：R733.3[医药卫生—肿瘤]